BioCina, an Australia-based contract development and manufacturing organisation (CDMO), announced on Tuesday that it has named Mark W. Womack as its new CEO.

In the new role, Womack will be responsible for the continued growth, commercial strategy and organisational culture of BioCina.

Womack has 30 years of experience across executive leadership, management consulting and CDMO commercial operations. He has served as CEO of KBI Biopharma and Selexis SA. He has also held the position of CEO and managing director of Stelis Biopharma and chief business officer at AGC Biologics. He started his career with over ten years of service in the US Navy.